Predicting Treatment Outcome in Stimulant Dependence

Martina Reske\textsuperscript{a} and Martin P. Paulus\textsuperscript{a, b}

\textsuperscript{a}Department of Psychiatry, University of California, San Diego, La Jolla, California, USA
\textsuperscript{b}Psychiatry Service, Veterans Affairs San Diego Health Care System, San Diego, California, USA

The purpose of this review is to highlight some of the issues that need to be addressed to optimally use functional neuroimaging as a clinical tool to predict outcomes in substance use disorders. First, the importance of recognizing the clinical heterogeneity of the substance use disorders population is highlighted. We also emphasize that empirical and theoretical analyses support the idea that the courses of substance use disorders are relatively independent of the types of substance being used. Second, various approaches to the measurement and characterization of the longitudinal courses of substance use disorders are summarized. Third, predictors of outcomes are reviewed and their limitations are discussed. Within this context, we describe aspects of our work that focus on using functional magnetic resonance imaging to predict outcomes. Fourth, we discuss future directions, critical experiments, and the utility of functional neuroimaging as a clinical tool.

Key words: addiction; stimulants; outcomes; prediction; fMRI; neuroimaging

Substance abuse and dependence have an enormous impact on society. For example, in the United States, the lifetime prevalence of substance abuse or dependence in adults is over 15%.\textsuperscript{1} The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health estimate that the cost was $246 billion in 1992, the most recent year for which sufficient data were available.\textsuperscript{2} In 2006, an estimated 20.4 million Americans aged 12 or older had used illicit drugs during the month prior to the survey; this represents 8.3% of the population aged 12 years or older.\textsuperscript{1} According to a Substance Abuse and Mental Health Services Administration report, 14.8 million individuals had used marijuana in the month prior to the survey, and illicit drugs other than marijuana were used by 9.6 million people. Rates of substance abuse and dependence are generally greater among men, Native Americans, individuals aged 18 to 44 years, those of lower socioeconomic status, those residing in the western part of the United States, and those who were never married or are widowed, separated, or divorced.\textsuperscript{3,4}

There is significant comorbidity between substance dependence and most mood disorders and anxiety disorders.\textsuperscript{4,5} Interestingly, only a minority of individuals with substance use disorders seek treatment.\textsuperscript{4} Psychiatric comorbidity has a profound influence on course and outcome. Individuals with substance use disorders and post-traumatic stress disorder, relative to those with substance use disorders only, are more impaired, have greater psychosocial problems, and show a more severe course.\textsuperscript{6} Similarly, comorbid antisocial personality disorder\textsuperscript{7} results in an earlier onset of substance use disorders, greater multisubstance use,\textsuperscript{8} poorer

---

Address for correspondence: Martin P. Paulus, Professor in Residence, Department of Psychiatry, Laboratory of Biological Dynamics and Theoretical Medicine, University of California San Diego, 8950 Villa La Jolla Dr., Suite C213, La Jolla, CA 92037-0985. UCSD: Voice: +858-534-9444; fax: +858-534-9450. VA: Voice: +858-642-3390; fax: +858-642-1429. mpaulus@ucsd.edu. Web: http://koso.ucsd.edu/~martin/index.html
A central characteristic of addictive behaviors is their chronically relapsing nature. Relapse is a complex process and includes multiple dimensions, such as the process prior to reuse of the drug, the event of using the drug, the level to which the use returns, and the consequences associated with use. Several models that stress cognitive-behavioral, person–situation interactional, cognitive appraisal, and outcome expectation factors have been put forth to explain the process of relapse. These models differ in the extent to which the focus is on the person (decreased self-efficacy), the situation (exposure to high-risk environments), and/or their interaction (insufficient mobilization of coping skills). On the other hand, psychobiological models of relapse have been based on opponent process and acquired motivation theories, craving or loss of control, urges or craving, withdrawal, and kindling processes. These models focus on the fact that brain reward systems become sensitized to drugs and drug-associated stimuli, resulting in increased “drug-wanting,” which increases the susceptibility to relapse. Some investigators have suggested that relapse is best understood as having multiple interactive determinants that vary in their temporal proximity from, and their relative influence on, relapse. Therefore, an adequate assessment and prediction model must be sufficiently comprehensive to include theoretically relevant variables from each of the multiple domains and different levels of potential predictors. Others have pointed out that relapse is not a binary but a continuous outcome across multiple dimensions, including the threshold, duration, prior sobriety level, number of substances involved, and consequences. Moreover, relapse encompasses a multidimensional response pattern with (1) the occurrence of negative life events; (2) cognitive appraisal variables, including self-efficacy, expectancies, and motivation for change; (3) subject coping resources; (4) craving experiences; and (5) affective/mood status.

Some investigators have suggested that aberrant learning processes within subcortical circuitry underlie aspects of observations that (1) drug-seeking behavior becomes compulsive and habitual and (2) the propensity for relapse to drug seeking can manifest even after long periods of sobriety. Others have suggested that substance use disorders are consequences of imbalances between overactive “impulsive” amygdala systems, which signal an immediate prospect of pain or pleasure, and a weakened “reflective” prefrontal cortex system for signaling possible future pain or pleasure. In particular, drugs and/or conditioned stimuli associated with drug availability are thought to overwhelm the goal-driven cognitive resources important for exercising the willpower to resist drugs. Finally, some have argued that substance dependence is characterized by an overvaluing of drug reinforcers associated with an undervaluing of alternative reinforcers in combination with deficits in inhibitory control. Based on animal experiments, Koob and LeMoal have conceptualized substance dependence, or addiction, as a cycle of increasing dysregulation of brain reward systems, which leads to compulsive drug use and a loss of control over drug taking. Both sensitization and counteradaptation processes contribute to this hedonic homeostatic dysregulation. The neurobiological mechanisms involved include the mesolimbic dopamine system, opioid peptidergic systems, and brain and hormonal stress systems.

Based on these views, it is clear that brain processes that are candidates for monitoring clinical states involve learning, drug and conditioned cue-related processing, homeostatic regulation, inhibition, and decision making.

**Predictors of Outcome**

A number of different domains have been tested for their ability to predict relapse. Here
Figure 1. Schematic for different stages of addictions. The goal for prediction tools in general and neuroimaging tools in particular is to be able to quantify the transitions with high positive and negative predictive value.

we segregate the results into four different factors: sociodemographic, clinical, psychological, and cognitive variables. The implications of these data for practical use in predicting clinical outcomes in addiction are limited, however, for a number of reasons. First, samples may be small, nonrepresentative, focused on subgroups of treatment-seeking individuals, and may only take a few substances into account. Second, outcome variables are varied and may consist of treatment adherence, relapse, or dropout from an ongoing program. Third, psychiatric comorbidity and diagnostic status are often not carefully defined. Nevertheless, the results from these studies focus our attention on possible candidate processes for functional neuroimaging studies.

Sociodemographic Factors

Employment status, history of injecting the drug of abuse, and sexual promiscuity during the 6 months prior to admission to a treatment program predict higher rates of relapse in cocaine-dependent subjects. Although patterns of use differ between male and female subjects, predictors of relapse, including residential instability, multiple drug use, single marital status, unemployment, an older age, and treatment dropout, differ less between genders. Some investigators have observed that being around other users accounted for nearly half of the relapse events. Family or work stress was associated with relapse in a third of the cases, and unpleasant affect in about a quarter of the cases. Some investigators have found higher relapse rates in subjects who had experienced significant negative life events in a 3-month period prior to relapse, although others did not find significant associations between life events and relapse. Higher severities of patient problems at the outset of treatment and shorter stays in treatment predicted higher relapse rates in cocaine-dependent subjects.

Findings by other groups also showed that a shorter treatment duration, older age of first substance use, involvement in selling methamphetamine, and more previous time in treatment predicted poorer treatment responses. Women in treatment who had multiple co-occurring addictions and depression showed higher rates of relapse. These results show that sociodemographic factors, circumstances, and perhaps gender may have an influence on the course of addiction.

Clinical Factors

Shorter delay between the onset of a mental health disorder and the beginning of outpatient mental health care has been associated with lower mortality and a better substance use outcome. Unfortunately, substance abuse treatment success rates, often little more than one-third of dependent individuals, are significantly lower than the 50%–60% success rates typical of treatment of other psychiatric disorders. Short-term abstinence at 6 months, which is predicted by older age, female gender, participation in a 12-step program, and association
with recovery-oriented social networks, is an important predictor of long-term abstinence at 5 years. Clinical comorbidities, such as polydrug abuse, psychiatric conditions, and a previous head injury may be associated with increases in impulsive decision making and subsequent greater risk of relapse. Similarly, increased psychiatric severity is a significant poor predictor of substance use outcomes. However, some investigators have noted that levels of anxiety symptoms at the beginning of treatment are not predictive of outcomes in cocaine users. In opiate-dependent individuals, a high level of pretreatment use of opiates or other drugs, prior treatment for opiate addiction, no prior abstinence from opiates, abstinence from or light use of alcohol, depression, high stress, unemployment or employment problems, association with substance-abusing peers, a short length of treatment, and leaving treatment prior to completion were found to be predict longitudinal course. Subjects with more severe consequences of drug use and less social exposure to drug use during treatment were found to show lower relapse rates during treatment. Taken together, outcomes are influenced by multiple clinical factors, although each factor by itself accounts for only a small portion of the variance.

Psychological Factors

Craving is an important psychological phenomenon that has been closely linked to relapse. In alcohol-using subjects, results of structured interviews that assess frequency and intensity of craving were able to correctly predict 75% of the subjects who relapsed to alcohol use. Similarly, craving intensity significantly predicted methamphetamine use in the week following each craving report. Craving remained a highly significant predictor in multivariate models that controlled for pharmacological intervention and for methamphetamine use during the prior week. Craving scores that preceded use were two to three times higher than scores that preceded abstinence. Similarly, risk of subsequent use was two to three times greater for scores in the upper half of the scale relative to scores in the lower half. Whereas 90% of subjects who reported no cravings for cocaine after treatment remained totally abstinent after 3 months, only a third of those who reported still having cravings after treatment were abstinent during this time.

Others have noted that experiences antecedent to relapse were almost exclusively negative emotional states (e.g., depression and loneliness). Preclinical research has shown that stress, in addition to drugs themselves, plays a key role in perpetuating drug abuse and relapse. However, many of the details concerning the mechanisms underlying this association in humans remain unclear. A greater understanding of how stress may perpetuate drug abuse will likely have a significant impact on both prevention and treatment development in the field of addiction. Interestingly, the degree of distress and satisfaction when entering treatment are not related reliably to dropout or relapse. Coping skills and use of coping strategies have also been related to relapse. Coping, as measured by a series of scales, which included social support, religious and community involvement, work, and recreational activities was able to correctly predict 85% of subjects relapsing to alcohol use. Moreover, coping factors reflecting problem-focused, social-support, self-blame, and wishful-thinking strategies successfully predicted 6-month outcome status in alcohol-dependent adolescents. By comparison, self-efficacy (defined as confidence in being able to resist the urge to drink heavily) assessed at intake of treatment, was strongly negatively associated with the level of consumption on drinking occasions at follow-up. Lower self-efficacy scores at intake predicted subsequent heavier drinking. Therefore, stress, coping, and the ability to modulate emotions are important processes to consider for predicting outcomes.

Several personality variables have been differentially associated with relapse. For example, higher levels of conscientiousness,
agreeableness, and extraversion were associated with greater confidence in the ability to refrain from use, whereas neuroticism was associated with a corresponding lack of confidence in self-restraint.\textsuperscript{54} High levels of neuroticism and conscientiousness predicted higher relapse rates.\textsuperscript{55} Orderliness and persistence factors on the Tridimensional Personality Questionnaire predicted longer latencies to relapse in alcohol-dependent subjects.\textsuperscript{56} Some investigators have related the diagnosis of antisocial personality disorder to the likelihood of relapse,\textsuperscript{56} whereas others did not show such an association.\textsuperscript{34} Accumulating evidence indicates that detached, dependent, and antisocial personality aspects increase the propensity to relapse.\textsuperscript{33} Higher scores on the Minnesota Multiphasic Personality Inventory (MMPI-2) Psychopathic Deviate scale predicted relapse in a Cox proportional hazard model among abstinent alcohol-dependent subjects.\textsuperscript{57} Among the different impulsivity dimensions, urgency (i.e., a tendency to act impulsively in response to negative emotional states) is a good predictor of severity of medical, employment, alcohol, drug, family or social, legal, and psychiatric problems in substance-dependent individuals. This factor explains 13\%–48\% of the total variance.\textsuperscript{38} In summary, as with clinical factors, psychological factors clearly influence outcome; however, a single outstanding predictor of long-term outcome has not been found.

**Cognitive and Physiological Factors**

Neuropsychological studies of substance abuse treatment outcome have found that individuals who recover successfully show intact functioning on most measures, whereas those who relapse do poorly on tests of language, abstract reasoning, planning, and cognitive flexibility.\textsuperscript{59} For example, approximately 74\% of subjects who recalled less than or equal to half of the items of the Product Recall Test relapsed at 3 months compared with only 33\% of the subjects who recalled more than half of the items.\textsuperscript{60} Consistent with the important role of the level of executive function as a risk for relapse, investigators have found that attention and executive functioning scores obtained at the intake neuropsychological assessment significantly predicted substance use and dependence symptoms 8 years later, even after controlling for intake substance involvement, gender, education, conduct disorder, family history of substance use disorders, and learning disabilities.\textsuperscript{61} Similarly, significant increases in attentional distraction for alcohol stimuli during 4 weeks of inpatient treatment were observed in alcohol-using subjects who relapsed or did not maintain postdischarge outpatient contact.\textsuperscript{62} Finally, higher verbal skills, as measured by the Shipley Institute of Living Scale, correctly predicted 64\% of subjects who did not relapse to using drugs or alcohol.\textsuperscript{63} A discriminant function analysis using the P300 amplitude in an event-related potential study during a selective visual attention task was able to identify 70\% of subjects with cocaine dependence who later relapsed, and 53\% of the subjects who did not.\textsuperscript{64} In addition, polysomnographic sleep latency has been found to be the most significant predictor of relapse in alcohol-dependent subjects.\textsuperscript{65} Decision making has been proposed to represent an essential ingredient for understanding relapse.\textsuperscript{66} Performance on two tests of decision making, but not on tests of planning, motor inhibition, reflection impulsivity, or delay discounting, was found to predict abstinence from illicit drugs at 3 months with high specificity and moderate sensitivity. In particular, two-thirds of the participants who performed normally on the Cambridge Gamble Task and the Iowa Gambling Task, but none of those who performed poorly on both, were abstinent from illicit drugs at follow-up.\textsuperscript{67} Others have found that a longer duration of the substance use disorder and neurocognitive indicators of disinhibition and decision making—but not self-reported impulsivity or reward sensitivity—were significant predictors of relapse.\textsuperscript{68} Although substance use disorder
individuals have significant deficits in the recognition of facial emotional expressions, these performance deficits were not related to the duration of abstinence, providing evidence for behavioral specificity. Thus, decision-making paradigms are good behavioral candidates to predict clinical outcomes. Refining these paradigms to better probe specific aspects of this complex process may enhance their prediction accuracy in the future.

In conclusion, relapse is a complex and multidimensional process. It is thus not surprising that multiple assessment domains can be related to relapse susceptibility. Surprisingly little research has been conducted to relate neurobiological variables to relapse susceptibility. Some of the cognitive variables that are known to correlate with increased risks for relapse, such as executive functioning, can be readily assessed using functional brain imaging. Thus, in addition to cognitive, psychophysiological, sociodemographic, social, and psychological tests, measurement of brain functioning during cognitively or emotionally challenging tasks may provide an important predictor of treatment outcome and greater insights into the nature of the cognitive and affective dysfunctions in substance-dependent subjects.

**Using fMRI to Predict Relapse**

Functional magnetic resonance imaging (fMRI) is a tool to map cognitive, affective, and experiential processes onto the brain regions that subserve them; fMRI is increasingly a method of choice to identify individual differences in many of these processes. Although the human brain constitutes only about 2% of the body’s mass, it accounts for approximately 20% of its total oxygen consumption. Deoxyhemoglobin has paramagnetic effects in the blood upon the nuclear magnetic resonance transverse relaxation times of water protons that reside nearby in the tissue. Blood oxygenation level–dependent (BOLD) fMRI is based on the fact that changes in blood oxygen levels affect the fraction of hemoglobin in the deoxygenated state and thus provide an MRI contrast agent. BOLD–fMRI experiments in the awake human visual cortex show that the ratio between BOLD–fMRI signal change and baseline signal is linearly proportional to the change in blood flow relative to the baseline blood flow. Moreover, increases in baseline blood flow are thought to be proportional to total deoxyhemoglobin within any volume element (voxel). For example, increasing cerebral blood flow using carbon dioxide administration reduces the BOLD response to the same task substantially. Therefore, the BOLD signal reflects the effect of neural activity on dynamic changes in cerebral blood flow, cerebral blood volume, and the cerebral rate of oxygen metabolism through a process generally referred to as neurovascular coupling. An often underappreciated aspect of BOLD–fMRI is that the interpretation of the results critically depends on the details of the task conducted during the imaging procedure. Whenever a neural substrate is described as “activated” in a study, or whenever two populations are described as differing in their activation patterns, one has to keep in mind that these differences are in the context of the task conducted. Further, fMRI measurements are of relative character, meaning that brain function during a task of interest, such as decision making, has to be related to a certain experimental baseline. The baseline itself can vary, and studies either use so-called low-level baselines, such as the display of a blank screen or fixation cross, or high-level baselines, for which an event with similar physical, but different cognitive, characteristics will be drawn on for statistical comparison. The nature of the reference baseline, itself, therefore influences the results. Taken together, fMRI is a proxy measure for how complex cognitive, emotional, social, and other experiential processes are implemented in different neural systems; it is not simply a matter of increases or decreases in activation of certain brain regions.

In a longitudinal study of methamphetamine-dependent individuals, we used a two-choice prediction task to probe simple decision-related processing. By comparing
brain activation during a two-choice response task relative to a two-choice prediction condition, we were able to separate sensorimotor processing from prediction and decision making. Individuals who engage in this task show bilateral activation of prefrontal cortex, striatum, posterior parietal cortex, and anterior insula during decision making. We found that individuals who relapsed, but not those who did not, showed attenuated or reversed activation patterns in prefrontal, parietal, and insular cortical regions. Optimized prediction calculations based on stepwise discriminant function analyses revealed that right insula, right posterior cingulate, and right middle temporal gyrus responses best differentiated between relapsing and nonrelapsing methamphetamine-dependent subjects. In combination, we obtained 94% sensitivity and 86% specificity using this approach. Using Cox regression analyses, we were able to predict time to relapse. This study demonstrated that the attenuated activation patterns during decision making may play a critical role in processes that set the stage for relapse.

Methodological Considerations

Although functional brain imaging has become a powerful tool to investigate the physiological basis of psychiatric or neurological disorders, it has only very recently been used to predict clinical outcomes in individual patients. Because MRI instruments are widely available, the use of this technology for identifying subjects at high risk and for predicting individual differences in treatment responses and relapses is particularly appealing. Such studies could provide insights into other psychiatric and neurological disorders with implications for the underlying assumptions and methodologies of fMRI.

Two major types of functional imaging studies are typically used: studies with only one and those with two imaging sessions. Extending the initial use of fMRI to characterize the neural correlates of major psychiatric symptoms, researchers have begun to develop study designs that incorporate fMRI into the diagnostic and treatment processes. Several cross-sectional studies using single functional brain scans have aimed at differentiating activations of healthy subjects, patients, and individuals who are at high risk (e.g., on genetic or other bases) for psychiatric disorders such as schizophrenia. In subsequent work, studies combined initial brain scans with psychopathological and neuropsychological reassessments in abstinent stimulant and cocaine users, and a small sample of abstinent alcoholics. These authors were able to differentiate brain activation patterns of patients with subsequent drug use from those of abstinent patients.

The practical relevance of post treatment brain scans for translational medicine seems to be limited because decisions about treatment selection and other clinical decisions often have to be made prior to the second, post treatment, imaging session. Nevertheless, functional imaging studies with two imaging sessions were among those used to monitor and predict the effects of specific treatments, such as cognitive-behavioral therapy in

Kosten and colleagues presented videotapes showing cocaine smoking to recently abstinent cocaine-dependent subjects while acquiring BOLD-fMRI and assessing craving. Activities in sensory, posterior cingulate, and superior temporal cortex as well as lingual and occipital gyri showed significant correlations with treatment effectiveness. Patients who subsequently relapsed or remained abstinent differed in their activation in the right temporal, precentral, left occipital, and posterior cingulate cortical regions. Such recent developments in fMRI study designs and analyses show that fMRI may become a useful tool to identify people at high risk of relapse to substance abuse at stages where both patients and therapists may have few other means for identifying such increased susceptibility to relapse. Preliminary results specifically highlight roles for the medial prefrontal cortex, the sensory cortex, the anterior and posterior cingulate gyri, the insula, and the right middle temporal gyrus in relapse processes.
depression or schizophrenia or in recovery after stroke.

**Statistical Approaches**

Several statistical approaches can be applied to predict future outcomes. Functional brain images are extraordinarily rich data sets that provide data concerning the time courses of activations of thousands of brain voxels. Type I errors have to be monitored adequately. For these reasons, hypothesis-driven region-of-interest approaches are now more frequently being used to limit the number of statistical comparisons. Simulation methods, such as Monte Carlo simulations, are applied to set statistical thresholds. Neighboring voxels may or may not belong to the same cell assembly; spatial smoothing, as applied in most imaging analysis routines, adds to activation overlays at some cost in terms of power to identify small regions of interest. Predictions based on patterns of neural activation thus face unique demands that need to be addressed by both statisticians and neuroscientists.

The few published papers that seek to use fMRI data to predict clinical outcomes adopt diverse analysis approaches. A set of baseline predictive variables has to be chosen and relevant imaging variables selected as the brain activation paradigm is chosen. Multivariate linear regression models using forward or stepwise regressions can determine the change in activation. However, if the number of baseline predictors is large, as will be true if whole-brain analyses are preformed, multiple regressions can be inappropriate. Multivariate approaches that include principal component analyses and/or partial least squares analyses (PLS) should then be considered. PLS analyses for fMRI data hold the advantage of assuming that cognitive tasks are processed in networks of voxels. Guo and colleagues recently introduced a Bayesian hierarchical model for positron emission tomography (PET) and fMRI data to forecast brain activity in schizophrenic patients following a specific treatment. In addition to the specific statistical model to be applied, future research will also have to identify which characteristics of brain activation will be relevant for clinical predictions. Candidate parameters include: the strength of the BOLD signal, the size of activated clusters, and the delay or shape of the hemodynamic responses.

**Ethical Implications**

As results from structural and functional imaging gain more relevance for predictions of responses in individual psychiatric and neurological patients, researchers will need to better anticipate and evaluate inherent ethical concerns. The medical and social consequences of predicting drug dependency or relapse based on functional brain images have to be acknowledged. Effects on health insurance and stigmatization are obvious issues. Measures to guarantee confidentiality will have to be identified. Individuals at high risk for relapse may be prone to increased stress from such testing and predictions, which themselves may increase relapse risks.

**Outcome—Beyond Relapse**

In simple terms, substance use disorders have been described as being absent or present, and relapse has been identified with the recurrence of the condition. However, the term relapse represents a somewhat arbitrary binary judgment imposed on a complex clinical condition. Moreover, the use of this term has been criticized because it connotes an unrealistic and inaccurate notion of the potential for successful change to occur over time. Thus, substance use disorders are not sufficiently quantified by presence or absence of abuse or dependence. Some investigators have argued that the expression of substance use disorders should be based on a general liability model across drug classes that results in a quantitative, rather than
The temporal expression of the substance use disorder phenotype of an individual can thus be viewed as the momentary probability that an individual will express a certain degree of substance use and associated problems. The Addiction Severity Index has been suggested as a reliable and valid instrument to quantify the severity of substance use disorders. Similarly, Timeline Follow-Back Latent trajectory class analysis is a useful method for aggregating individuals who have similar symptom patterns over time into course-of-illness groups. This statistical approach may have a quantitative advantage over rules-based assignment using a priori criteria because it attempts to maximize the extraction of information from empirical data rather than following a specific operational convention of rules. Recently, latent trajectory class approaches have been used to examine substance use trajectories. These approaches reveal substantial commonality for disorders associated with a variety of substance types. Most follow similar longitudinal courses irrespective of the particular drug used. Others have argued that a number of factors, such as age, type of substance, problem severity, and chronicity, influence the longitudinal expression of substance use disorders. Specifically, six trajectory classes have been identified in men with substance use disorders. These classes include individuals with early-onset and severe substance use disorder symptoms persisting into adulthood, individuals with early-onset substance use disorder symptoms who improve over time, and others with symptoms that emerage later and with varying degrees of severity and persistence. Other investigators have found associations between the longitudinal courses of substance use disorders and psychiatric comorbidity, marital status, and employment status. Using similar approaches in individuals with alcohol or tobacco use disorders, five different trajectory types were found; these were associated with densities of family history of substance abuse, gender, alcohol expectancy, behavioral undercontrol, and childhood stressors. In summary, the longitudinal expression of substance use disorder is complex, nonuniform, and may not be adequately quantified by a binary state of relapse. Therefore, predicting outcomes using functional neuroimaging or other measures may need to focus on drug use trajectories rather than relapse versus nonrelapse.

**The Future of Neuroimaging in Addiction**

In a recent study with neurologically disordered individuals, investigators cited five potential roles for neuroimaging with respect to dementia: (1) as a cognitive neuroscience research tool, (2) for prediction of which normal or slightly impaired individuals will develop dementia and over what timeframe, (3) for early diagnosis of Alzheimer’s disease (AD) in demented individuals (sensitivity) and separation of AD from other forms of dementia (specificity), (4) for monitoring of disease progression, and (5) for monitoring responses to therapies. Interestingly, neurologists have shown that lower motor cortex activation using fMRI was the best predictor of improvement and increases in motor cortex activation after treatment for stroke. Such roles for neuroimaging are not unlike those that we would like to see implemented in the field of addiction. Substance-dependent individuals constitute a heterogeneous group for which the factors reviewed above contribute to individual outcomes. The value of functional neuroimaging on its own—compared with clinical, sociodemographic, and neuropsychological variables—for the prediction of relapse in substance abuse has not been clearly delineated. A combination of data from all of those modalities, however, may soon enable the clinician to deduce individual predictions, even though current imaging studies rely on group analyses. Further, other functional brain imaging techniques such as PET, single-photon emission computed tomography (SPECT),
and magnetoencephalography (MEG), have already proven their relevance in predicting mild cognitive impairment\textsuperscript{100} and depression\textsuperscript{101} and may also be useful for the prediction of relapse to stimulant use. Predictions for clinical outcomes based on fMRI data could already be made in a limited number of published studies. It has been hypothesized that predictions of therapy-related behavioral gains may most accurately be achieved when acquiring baseline measures of both brain function and clinical variables.\textsuperscript{86} Drug cue–induced brain activation can distinguish between subjects who subsequently remain abstinent or relapse\textsuperscript{102} and can be a better predictor of relapse than subjective reports of craving.\textsuperscript{78} Once functional imaging has been adopted into prediction processes, researchers will have to evaluate its use to select potential subsequent treatments. Brain function data can also help trigger special clinical interventions. Neurofeedback, for example, may offer a promising tool to increase or suppress abnormalities in neural activity that could enhance individuals’ abilities to abstain from substances.

For neuroimaging to play a critical clinical role in predicting outcomes in substance use disorders, its sensitivity and specificity must be documented. Thus far, most imaging studies have revealed intriguing systems neuroscience results at the level of groups of subjects. These findings, by themselves, are insufficient to help move imaging forward as a clinically relevant tool. On the other hand, most imaging studies have demonstrated surprisingly large effect sizes, which supports the idea that differences across individuals and across time within individuals may be large enough to provide meaningful results when measured on a subject-by-subject basis. To be useful as an illness severity marker or relapse predictor, neuroimaging measures need to closely track disease state both when the disorder is symptomatic and when it is asymptomatic. Thus, it is not sufficient to show that ill individuals differ from healthy subjects; rather, it must also show that recovered or asymptomatic individuals with substance use disorders have altered processing in specific brain structures compared with individuals without substance use disorders. Such consistent distinctions would enable us to make clinical predictions about individuals who are at high risk for exacerbation of substance use symptoms. As others have pointed out, combining neuroimaging approaches within medication studies of cocaine abusers could prove useful for targeting specific pharmacological agents to subgroups of patients, prediction of response to medication, and relapse to use.\textsuperscript{103} Clearly, functional neuroimaging is playing an important role in substance use disorder research. For this modality to be useful in defining diagnostic categories or monitoring treatment success, we need to push the limits of the technology to clearly show its ability to define clinically relevant information on a single-subject basis.

Acknowledgments

This research was supported by grants from the National Institute on Drug Abuse (R01DA016663, R01DA018307) and by a Veterans Affairs Merit Grant.

Conflicts of Interest

The authors declare no conflicts of interest.

References


89. Guo, Y., F. Dubois Bowman & C. Kilts. 2007. Predicting the brain response to treatment using
a Bayesian hierarchical model with application to a study of schizophrenia. *Hum. Brain Mapp.* Available at www3.interscience.wiley.com/cgi-bin/fulltext/116328838/htmlstart.


